Clinical Trial: MA-CRC-II-016 SHR-1811

U.S., Jan. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07355764) titled 'MA-CRC-II-016 SHR-1811' on Dec. 17, 2025.

Brief Summary: A randomized, controlled, multicenter clinical study of SHR-A1811 combined with bevacizumab for the second-line treatment of metastatic colorectal cancer

Study Start Date: Dec. 30, 2025

Study Type: INTERVENTIONAL

Condition: mCRC HER2 Targeted Therapy Antibody-drug Conjugates

Intervention: DRUG: SHR-A1811 & Bevacizumab injection

HER2 ADC

DRUG: Chemotherapeutic Combinations

FOLFIRI+BEV

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Peking Union Medical College Hospital

Information provided by (Responsible Party): Xicheng Wang, Peking Union Medical College Hospital ...